Betahistine dihydrochloride

CLINICAL USE


Treatment of vertigo, tinnitus and hearing loss associated with Ménière’s syndrome

DOSE IN NORMAL RENAL FUNCTION

8–16 mg, 3 times a day

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :209.1
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :0–5
  • %Excreted unchanged in urine &nbsp &nbsp : 85–90

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :No data

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :3.4/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 8–16 mg, 2–3 times a day

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Likely dialysability. Dose as in GFR <10 mL/min

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Likely dialysability. Dose as in GFR <10 mL/min
  • HDF/high flux &nbsp :Likely dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Likely dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

  • Betahistine is rapidly and completely absorbed after oral administration
  • It is excreted almost exclusively in the urine as 2-pyridylacetic acid within 24 hours of administration
    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt